Celontin (methsuximide) NDC 0071-0525

NDC codes

FDA NDC Directory

Product NDC (as listed)0071-0525Labeler and product segments. Claims need a package NDC.

Product NDC at billing width00071-0525Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
0071-0525-24	00071052524	100 CAPSULE in 1 BOTTLE (0071-0525-24)Marketed from Feb 8, 1957

How the 11-digit form is made: The labeler segment has 4 digits, so one leading zero is added to it (4-4-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Celontin
Generic name (nonproprietary): methsuximide
Active ingredients: Methsuximide — 300 mg/1
Dosage form: Capsule
Route: Oral
Labeler: Parke-Davis Div of Pfizer Inc
Product type: Prescription drug
Marketing category: NDA — New Drug ApplicationApplication NDA 010596
Marketing start: Feb 8, 1957
Listing expires: Dec 31, 2027
Other FDA classes: Decreased Central Nervous System Disorganized Electrical Activity (Physiologic effect)
Identifiers: Product ID 0071-0525_5d3eee75-8d10-4969-b883-81b1d5d3ae97SPL ID 5d3eee75-8d10-4969-b883-81b1d5d3ae97SPL set ID 64a6ee88-c6b1-4e13-8208-b6772ef65a74RxCUI 197949, 207088UNII 0G76K8X6C0UPC 0300710525245
Pharmacologic class: Anti-epileptic Agent

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N400071052524 followed by a unit qualifier and the quantity

Package 00071-0525-24. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Apr 7, 2026.

Indications (excerpt from the label)

INDICATIONS AND USAGE Celontin is indicated for the control of absence (petit mal) seizures that are refractory to other drugs.

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)